Followers | 839 |
Posts | 120538 |
Boards Moderated | 14 |
Alias Born | 09/05/2002 |
Tuesday, November 02, 2021 9:13:20 AM
https://investors.evolus.com/news-releases/news-release-details/evolus-reports-third-quarter-2021-results-and-provides-business
3Q21 Jeuveau sales of $26.7M were up 2% from $26.7M in 2Q21. Jeuveau sales for the 12-month period through 9/30/21 were $85.6M.
EOLS still exprcts an EU launch of Jeuveau in 2022.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent EOLS News
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 09/28/2024 01:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/07/2024 01:45:54 AM
- Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024 • Business Wire • 09/06/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 08:14:51 PM
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 08/09/2024 08:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 09:00:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 08:12:11 PM
- Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance • Business Wire • 07/31/2024 08:05:00 PM
- Evolus to Hold Investor Day on September 12, 2024 • Business Wire • 07/31/2024 12:00:00 PM
- Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia • Business Wire • 07/30/2024 12:00:00 PM
- Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference • Business Wire • 07/25/2024 12:00:00 PM
- Evolus to Report Second Quarter Financial Results on July 31, 2024 • Business Wire • 07/17/2024 12:00:00 PM
- Evolus Announces Appointment of Albert G. White III to Board of Directors • Business Wire • 07/01/2024 12:00:00 PM
- Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products • Business Wire • 06/24/2024 12:00:00 PM
- Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain • Business Wire • 06/12/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:05:21 PM
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 06/07/2024 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 11:01:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/06/2024 09:45:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 01:30:56 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/05/2024 09:22:34 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/04/2024 08:25:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 09:53:10 PM
- Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting • Business Wire • 05/20/2024 12:30:00 PM
FEATURED CBD Life Sciences, Inc. (CBDL) Reaches Unprecedented Heights With Explosive Growth and Strategic Expansion in 2024 • Oct 8, 2024 8:00 AM
BNCM COMPLETES MERGER WITH DELEX HEALTHCARE • BNCM • Oct 8, 2024 9:54 AM
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM